Vor Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: VOR · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $0, $55.6 million, $0.838 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, sec-filing
TL;DR
Vor Bio inked a deal and sold some stock, filing an 8-K on Dec 26.
AI Summary
On December 26, 2024, Vor Biopharma Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided other event information. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates significant corporate activity, including a material definitive agreement and unregistered equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-39979 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1591163 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- December 26, 2024 (date) — Date of earliest event reported
- 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Vor Biopharma Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 26, 2024.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported was on December 26, 2024.
What is Vor Biopharma Inc.'s principal executive office address?
The principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140.
Under which sections of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What are the main items of information disclosed in this 8-K filing?
The filing includes information on the entry into a material definitive agreement, unregistered sales of equity securities, Regulation FD disclosure, other events, and financial statements and exhibits.
Filing Stats: 1,840 words · 7 min read · ~6 pages · Grade level 13.4 · Accepted 2024-12-27 09:05:53
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $0 — e per Share and Common Stock Warrant of $0.99425, for gross proceeds of approximat
- $55.6 million — 25, for gross proceeds of approximately $55.6 million (the "Private Placement"). The Purchase
- $0.838 — Stock Warrant has an exercise price of $0.838 per Warrant Share. The Common Stock War
Filing Documents
- d865206d8k.htm (8-K) — 35KB
- d865206dex41.htm (EX-4.1) — 70KB
- d865206dex101.htm (EX-10.1) — 181KB
- d865206dex102.htm (EX-10.2) — 76KB
- d865206dex991.htm (EX-99.1) — 12KB
- g865206g1227120512626.jpg (GRAPHIC) — 2KB
- 0001193125-24-285627.txt ( ) — 607KB
- vor-20241226.xsd (EX-101.SCH) — 3KB
- vor-20241226_lab.xml (EX-101.LAB) — 18KB
- vor-20241226_pre.xml (EX-101.PRE) — 11KB
- d865206d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "aim," "anticipate," "can," "continue," "could," "design," "enable," "expect," "initiate," "intend," "may," "on-track," "ongoing," "plan," "potential," "should," "target," "update," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Current Report on Form 8-K include the Company's expectations regarding the closing of the Private Placement and the use of proceeds therefrom, the anticipated filing of a registration statement to cover resales of the Shares and Warrant Shares, the timing of the availability and announcement of data from its clinical trials, including the Phase 1/2 VBP301 trial of VCAR33 ALLO and the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg, and its expected cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; the success of the Company's in-house manufacturing capabilities and efforts; and availability of fundi
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. By: /s/ Robert Ang Robert Ang Chief Executive Officer Date: December 27, 2024